Literature DB >> 1438031

Single dose pharmacokinetics of trazodone in healthy subjects.

O G Nilsen1, O Dale.   

Abstract

Eight healthy subjects were administered trazodone-HCl orally (100 mg) with and without food and by infusion in a three way cross-over study. Unchanged trazodone was determined in serum and urine by high performance liquid chromatography after an alkaline extraction. Absorption of trazodone was irregular in fasting subjects and improved after food intake. Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr. No differences were observed in the total amount of trazodone absorbed with or without food with bioavailability values of 65 +/- 6 and 63 +/- 4 per cent, respectively. The apparent volume of distribution and total body clearance for trazodone were estimated to 0.84 +/- 0.16 l/kg and 5.3 +/- 0.9 l/hr, respectively. The terminal elimination half-life of 7.3 +/- 0.8 hr showed no significant differences between the different ways of administration. Urinary excretion of unchanged trazodone during 26 hr was less than 0.13 per cent of the administered dose, suggesting a high degree of trazodone metabolism. Earlier statements of enterohepatic circulation of trazodone and pharmacokinetic differences between males and females were not confirmed by the present study. Due to the irregular absorption in fasting subjects, trazodone should preferably be administered after food.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1438031     DOI: 10.1111/j.1600-0773.1992.tb00535.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  8 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.

Authors:  M Haria; A Fitton; D McTavish
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

Review 4.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

5.  Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations.

Authors:  Laura Oggianu; Giorgio Di Dato; Giorgina Mangano; Maria Teresa Rosignoli; Savannah McFeely; Alice Ban Ke; Hannah M Jones; Alessandro Comandini
Journal:  Clin Transl Sci       Date:  2022-03-02       Impact factor: 4.438

6.  Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition.

Authors:  Prashant Kale; Yadvendra K Agrawal
Journal:  Front Pharmacol       Date:  2015-10-02       Impact factor: 5.810

7.  Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction.

Authors:  Laura Oggianu; Alice B Ke; Manoranjenni Chetty; Rossella Picollo; Vanessa Petrucci; Fabrizio Calisti; Fabio Garofolo; Serena Tongiani
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-01-11

8.  Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse.

Authors:  J L Davis; J Schirmer; E Medlin
Journal:  J Vet Pharmacol Ther       Date:  2018-01-14       Impact factor: 1.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.